Department of Endocrinology and Metabolism and Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Department of Internal Medicine, Dijklander Ziekenhuis, Hoorn, the Netherlands.
Clin Nutr. 2024 Nov;43(11):99-105. doi: 10.1016/j.clnu.2024.08.031. Epub 2024 Sep 21.
BACKGROUND & AIMS: Obesity is associated with vitamin D (VitD) deficiency. However, previous studies showed mixed effects of VitD (25-hydroxyVitD/calcidiol) supplementation on body weight. The biological actions of VitD require the hydroxylation of inactive VitD into active VitD (1.25-dihydroxyVitD/calcitriol). This step is highly regulated; therefore, supplementing with inactive VitD might not be sufficient to overcome the potential adverse health effects of VitD deficiency. The objective of this study was to conduct a systematic review and individual participant data (IPD) meta-analysis of data acquired from randomised placebo-controlled calcitriol trials (RCTs) to determine the effects of calcitriol on body weight and weight-related parameters.
Studies were identified from MEDLINE, EMBASE, and CENTRAL databases up to January 27, 2024, and excluded those involving dialysis or cancer patients. We obtained IPD from eligible trials and assessed bias using the Cochrane Collaboration risk-of-bias tool and methodological quality using the Heyland Methodological Quality Score. The study was prospectively registered with PROSPERO (CRD42017076202).
Although none of the studies reported information regarding our primary objective, we obtained IPD for 411 patients, with 206 randomised to receive calcitriol and 205 to placebo. This dataset enabled us to conduct an IPD meta-analysis with 17,084 person-months of follow-up (median: 11 months). Meta-analysis showed that calcitriol does not alter body weight, BMI, waist circumference, fat mass or lean body mass compared to placebo. Adjusting for age and sex did not alter the outcomes.
In conclusion, this systematic review and IPD meta-analysis indicate that calcitriol does not affect body weight in normal-weight postmenopausal women and lean patients with type 1 diabetes nor in people suffering from obesity, type 2 diabetes and chronic kidney disease. Whether calcitriol lowers body weight in VitD-sufficient people with obesity remains to be elucidated.
肥胖与维生素 D(VitD)缺乏有关。然而,先前的研究表明 VitD(25-羟化 VitD/钙二醇)补充对体重的影响不一。VitD 的生物学作用需要将无活性的 VitD 羟化为活性的 VitD(1,25-二羟化 VitD/钙三醇)。这一步受到高度调控;因此,补充无活性的 VitD 可能不足以克服 VitD 缺乏潜在的不良健康影响。本研究的目的是对随机安慰剂对照钙三醇试验(RCT)获得的数据进行系统评价和个体参与者数据(IPD)荟萃分析,以确定钙三醇对体重和体重相关参数的影响。
从 MEDLINE、EMBASE 和 CENTRAL 数据库中检索截至 2024 年 1 月 27 日的研究,并排除涉及透析或癌症患者的研究。我们从合格的试验中获取 IPD,并使用 Cochrane 协作风险偏倚工具评估偏倚,使用 Heyland 方法学质量评分评估方法学质量。该研究已在 PROSPERO(CRD42017076202)上进行了前瞻性注册。
尽管没有一项研究报告了我们主要目标的信息,但我们获得了 411 名患者的 IPD,其中 206 名随机接受钙三醇治疗,205 名接受安慰剂治疗。这个数据集使我们能够进行 IPD 荟萃分析,随访时间为 17,084 人月(中位数:11 个月)。荟萃分析表明,与安慰剂相比,钙三醇不会改变体重、BMI、腰围、脂肪量或瘦体重。调整年龄和性别并没有改变结果。
总之,这项系统评价和 IPD 荟萃分析表明,钙三醇不会影响正常体重绝经后妇女和 1 型糖尿病的瘦患者的体重,也不会影响肥胖、2 型糖尿病和慢性肾脏病患者的体重。钙三醇是否会降低肥胖 VitD 充足人群的体重仍有待阐明。